85%Confidence
0Views
FDASource
2026-04-21Date
Summary
Fagron faces a product recall due to sterility concerns and a potential for part detachment in a compounded vancomycin product. This signals quality control issues that could impact its compounding services business and regulatory standing.
Actionable: Monitor Fagron's stock for negative sentiment and potential financial impact from recall costs and reputational damage.
AI Confidence: 85%
Data Points
firmFagron Compounding Services
classificationClass II
statusOngoing
distributionNationwide in the U.S.A.
productVancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now